欧林生物: 成都欧林生物科技股份有限公司高级管理人员减持股份计划公告

Core Viewpoint - Senior management personnel of Chengdu Olin Biological Technology Co., Ltd. plan to reduce their shareholdings due to personal financial needs, with specific limits on the number of shares to be sold and the timeframe for the reduction [1][2][3]. Summary by Relevant Sections 1. Basic Information of Senior Management Shareholdings - As of the announcement date, the financial officer and deputy general manager, Mr. Tan Yong, holds 571,440 shares, accounting for 0.14% of the company, with 277,440 shares obtained before the IPO and 238,000 shares through other means [2]. - The company secretary and deputy general manager, Mr. Wu Wei, holds 778,400 shares, accounting for 0.19% of the company, with 204,000 shares obtained before the IPO and 510,000 shares through other means [2]. 2. Details of the Reduction Plan - Mr. Tan plans to reduce his holdings by no more than 128,860 shares, representing up to 0.0317% of the total shares [2][3]. - Mr. Wu plans to reduce his holdings by no more than 178,500 shares, representing up to 0.0440% of the total shares [3]. - The reduction will occur through centralized bidding and block trading from September 26, 2025, to December 25, 2025 [3]. 3. Reasons for Reduction - The reduction is primarily due to personal financial needs of the senior management personnel [3]. 4. Compliance and Commitments - Both Mr. Tan and Mr. Wu have committed to not reducing their pre-IPO shares within a complete accounting year and have agreed to adhere to relevant regulations regarding share transfers [3][4].